Carlsbad, California--(Newsfile Corp. - May 2, 2024) - CB Therapeutics, a leading biotechnology firm
specializing in precision fermentation, announces groundbreaking advancements in the production of
pharmaceutical-grade cannabinoids and their analogs. With the recent reclassification of cannabinoids,
the company hopes to revolutionize the pharmaceutical industry by offering a sustainable, standardized
solution for cannabinoid therapeutics.
The utilization of precision fermentation technology marks a significant departure from conventional
methods of cannabinoid extraction from hemp and cannabis plants. By harnessing the power of
fermentation, CB Therapeutics ensures consistent, high-quality production of cannabinoids and their
analogs, addressing the inherent variability and challenges associated with traditional cultivation
methods. This innovative approach not only streamlines the manufacturing process but also guarantees
the purity and safety of the final pharmaceutical products.
"Our precision fermentation platform represents a paradigm shift in cannabinoid production, offering a
sustainable and eco-friendly alternative to traditional cultivation methods," remarked Sher Butt, President
and CEO of CB Therapeutics. "We are committed to providing pharmaceutical companies with a reliable
source of pharma-grade cannabinoids, empowering them to develop life-saving and life-changing
therapeutics with confidence."
In addition to delivering standardized and contaminant-free cannabinoids, CB Therapeutics' precision
fermentation process boasts remarkable eco-friendly credentials. Compared to conventional cultivation
practices, precision fermentation significantly reduces resource consumption, carbon emissions, and
environmental impact. This sustainable approach aligns with the growing demand for environmentally
responsible solutions in the pharmaceutical industry, offering companies a compelling option for their
cannabinoid-based therapeutics.
"We recognize the importance of simplicity and accessibility in the pharmaceutical sector," stated Jacob
Vogan, Chief Science Officer at CB Therapeutics. "Our precision fermentation technology is designed to be
user-friendly and scalable, enabling seamless integration into existing pharmaceutical workflows. We are
dedicated to empowering pharma and biotech companies with the tools they need to drive innovation and
make a meaningful impact on global health."
With its cutting-edge technology and unwavering commitment to sustainability and quality, CB
Therapeutics hopes to lead the charge in cannabinoid therapeutics. The company looks forward to
collaborating with pharmaceutical and biotech partners to unlock the full potential of cannabinoids and
accelerate the development of next-generation treatments for patients worldwide.